Publications by authors named "Gary Sopher"

Claim this Profile
C
Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.
Paolo Tarantino, Sarah Sammons, V K Gadi, Purnima Pathak, Gary Sopher

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.
Sarah Sammons, Paolo Tarantino, V K Gadi, Purnima Pathak, Gary Sopher

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Sarah Sammons, Denise A Yardley, Priyanka Sharma, Vijayakrishna K Gadi, Mark Pegram, Gary Sopher

Oncol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
Lowell L Hart, Seock-Ah Im, Sara M Tolaney, Mario Campone, Timothy Pluard, Gary Sopher

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis